Clinical trial NCT04954183: Development of an EEG Diagnostic for Alzheimer's Disease
Official title: Development of an EEG Diagnostic for Alzheimer's Disease: A Feasibility Study
Study type: OBSERVATIONAL
Overall status: ENROLLING_BY_INVITATION
Conditions: Mild Cognitive Impairment
Alzheimer Disease
Dementia With Lewy Bodies
Normal Control APOE e4 Carriers and Noncarriers
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
Collaborators: name: Spark Neuro Inc.
First posted: 2021-07-08
Enrollment: 30
Sex: ALL
Minimum age (years): 50
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Subjects with moderate to severe dementia, mild stage dementia, amnestic MCI, presymptomatic APOE e4 carriers, and age, sex, and education matched APOE e4 noncarriers will be recruited at Mayo Clinic Arizona to obtain EEG data.

Brief summary: The purpose of this research is to collect and compare electroencephalogram data from all stages of Alzheimer's disease from preclinical through severe dementia.

Detailed description: Patients with diagnoses of sporadic and late onset Alzheimer's disease dementia, MCI, and DLB evaluated by a dementia subspecialist will meet published diagnostic criteria, and EEGs will be obtained through written informed consent. Regarding presymptomatic patients, we have previously shown that the mean age of MCI diagnosis in our cohort is 73 years and that preclinical cognitive decline begins as much as 20 years before clinical diagnosis but is also affected by APOE genotype. Eligibility therefore will include unimpaired APOE e4/4 homozygotes age 65-75 and APOE e3/4 heterozygotes age 75-85 for the preclinical AD subset and age, sex, and education matched APOE e4 noncarriers for the unaffected controls. Biomarker confirmation for preclinical diagnosis will be utilized to the extent possible (a subset of 130 members of our cohort have undergone amyloid-PET resulting in approximately 45 who are amyloid positive). EEG data will be performed during wakefulness with 15 minutes of eyes open and 15 minutes of eyes closed. A 32 electrode cap will be applied following the 10-20 anatomical system by certified EEG technologists. Data will be recorded using a research-grade EEG system with FDA 510(k) clearance for use in medical contexts. Subjects will be seated in a testing room with minimal distractions. An EEG tech will fit the subject with a cap containing NN Ag/AgCl electrodes placed according to the international 10-10 system and ensure electrode impedances stay below 10 kΩ. Subjects will be instructed to minimize movements and remain in a relaxed but wakeful state. We will record fifteen minutes of eyes-open resting state EEG. Afterwards, the subjects will be instructed to close their eyes and reminded to stay relaxed but awake, and we will record fifteen minutes of eyes-closed resting state EEG. During the recording session, a researcher will monitor the subject's behavior and the EEG signal. The researcher will briefly prompt the subject to remain awake if the subject's behavior or EEG traces show signs of drowsiness. All data will be de-identified then transferred to SPARK Neuro's research and development team for analysis via secure encrypted methods. The data will be stored on password-protected computer systems, and only the necessary research and research-support staff at SPARK Neuro will have access to the data. The SPARK Neuro research and development team will analyze de-identified patient data to address the aims of this proposal. SPARK Neuro will use various techniques including those standard in EEG analysis (e.g. filtering, scaling, independent components analysis), particular approaches shown to be successful in the Alzheimer's disease EEG classification literature (e.g. coherence, relative power in standard frequency bands, functional connectivity, spectral entropy), as well as approaches from the broader machine-learning and EEG literature (e.g. spectral clustering, convolutional neural networks, cross-frequency coupling, non-linear kernels, Katz fractal dimension, beamforming).

Eligibility criteria: Inclusion Criteria:

* 5 individuals with moderate to severe dementia, 5 with mild stage dementia, 5 with amnestic MCI, 5 presymptomatic APOE e4 carriers, and 5 age, sex, and education matched APOE e4 noncarriers. Additionally we will include a group of 5 patients with mild to moderate stage dementia with Lewy bodies (DLB), the second most common degenerative dementia, to explore differences from clinically typical Alzheimer's disease patients given the known clinical differences in EEG dysrhythmic severity between them (total of 30).
* Unimpaired APOE e4/4 homozygotes age 65-75 and APOE e3/4 heterozygotes age 75-85 for the preclinical AD subset and age, sex, and education matched APOE e4 noncarriers for the unaffected controls.
* Biomarker confirmation for preclinical diagnosis will be utilized to the extent possible (a subset of 130 members of our cohort have undergone amyloid-PET resulting in approximately 45 who are amyloid positive).

Exclusion Criteria:

* Previous stroke.
* Severe head injury.
* Craniotomy.
* Any other potentially confounding neurologic illness (typically anything that causes structural brain damage).
* Psychoactive medication use will not be an absolute exclusionary criterion in patients with moderate to severe dementia but patients who are relatively drug-free will be prioritized to the extent they are available within the study period.
* Psychoactive drug use will be exclusionary in the prospectively obtained clinical patients.

Primary outcomes:
measure: Obtain electroencephalogram (EEG) data
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Scottsdale
country: United States
facility: Mayo Clinic in Arizona
state: Arizona
Study officials:
affiliation: Mayo Clinic
name: Erik K. St. Louis, MD
role: PRINCIPAL_INVESTIGATOR
References: